At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 310 enrolled
Drug / intervention
Olaratumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating Olaratumab, Gemcitabine, and 2 other interventions for Soft Tissue Sarcoma. Completed, enrolled 310 participants across 48 sites in 10 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesAustralia, France, Germany, Hungary, Israel, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionJul 2020
Study CompletionApr 2021
TodayJul 2026
First PostedJan 20, 2016
Enrollment StartMar 1, 2016
Primary CompletionJul 28, 2020
Study CompletionApr 27, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.5 years ago
Interventions
Olaratumabdrug
Administered IV
Gemcitabinedrug
Administered IV
Docetaxeldrug
Administered IV
Placebodrug
Administered IV